Senzime AB (publ) has completed a directed issue. The issue provides Senzime approximately SEK 10 million before issue costs and the company intends to use the proceeds from the private placement to strengthen working capital, among other things, finance the ongoing operations of the recently acquired MD Biomedical AB.
Senzime develops and sells products for the healthcare and pharmaceutical production.
Redeye AB has acted as financial advisor and Lindahl legal advisor in connection with the issue.
Lindahl's team consisted of Mattias Prage (lead partner), Helena Lindbäck , Sofia Lysén and Marcus Andersson.